Blockade of anti-phagocytic CD47-SIRPα interactions using humanized antibodies to CD47 (Hu5F9-G4) has yielded promising results in preclinical studies of a number of human malignancies including pediatric brain tumors: medulloblastoma, atypical teratoid rhabdoid tumors, primitive neuroectodermal tumor, pediatric glioblastoma, and diffuse intrinsic pontine glioma (Gholamin et al., 2017) and accelerates the clearance of hematomas in experimental intraventricular hemorrhage (Ye et al., 2021). The gene discussed is CD47; the disease is primitive neuroectodermal tumor.